(Q43781929)

26 November 2017

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study (English)

1 reference

26 November 2017

3

1 reference

26 November 2017

8

Kantoff PW

1 reference

26 November 2017

Smith MR

1

1 reference

26 November 2017

Kaufman D

2

1 reference

26 November 2017

Guerin K

4

1 reference

26 November 2017

Seiden M

5

1 reference

26 November 2017

Makatsoris T

6

1 reference

26 November 2017

Manola J

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

26 November 2017

1 reference

26 November 2017

89

1 reference

26 November 2017

8

1 reference

26 November 2017

1824-1828

1 reference

Chemotherapy for advanced hormone refractory prostate cancer

26 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

21 January 2018

Vinorelbine: an overview

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

The treatment of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Estramustine Phosphate Sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Clinical pharmacokinetics of estramustine phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Longitudinal myotomy of ileum for bladder replacement in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

What is the maximum number of levels needed in pain intensity measurement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1824%3A%3AAID-CNCR24%3E3.0.CO%3B2-R

10.1002/1097-0142(20001015)89:8<1824::AID-CNCR24>3.0.CO;2-R

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference